Single Dose Escalation Study in Patients With Chronic Heart Failure
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study is to demonstrate the safety and tolerability of a single oral dose of BAY60-4552
in a single dose escalation design. Furthermore, this study examines the changes in
hemodynamics after application of the test substance.42 hospitalized stable patients with
chronic heart failure will be included. Several measurements will be performed to test how
good the drug works and wether there are any unwanted reactions to the drug (e.g. blood
tests, ECG, heart rate, blood pressure, adverse events). After a observation period the
patient will be discharged from the hospital.